OCA
PFE icon

OpenArc Corporate Advisory’s Pfizer PFE Stock Holding History

OpenArc Corporate Advisory’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
54,563
+5,818
+12% +$152K 0.02% 306
2026
Q1 		$1.37M Buy
48,745
+10,255
+27% +$273K 0.02% 289
2025
Q4 		$958K Buy
+38,490
New +$971K 0.02% 304

Other funds holding PFE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OpenArc Corporate Advisory's PFE Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Pfizer (PFE) stake by 12% in Q2 2026, buying an estimated $152K and bringing the position to 54,563 shares worth $1.31M. The position accounts for 0.02% of the portfolio, ranked #306.

OpenArc Corporate Advisory first reported a position in PFE in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.37M in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • OpenArc Corporate Advisory held 54,563 shares of Pfizer worth $1.31M as of Q2 2026.
  • OpenArc Corporate Advisory bought 5,818 Pfizer shares in Q2 2026, an estimated $152K.
  • Pfizer made up 0.02% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #306 holding.
  • OpenArc Corporate Advisory first reported a position in Pfizer in Q4 2025 and has held it in 3 quarters since.
  • OpenArc Corporate Advisory's Pfizer position peaked at $1.37M in Q1 2026.
  • 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.